ICER, advocates prep for tense meeting on Sarepta's Duchenne drugs
July 24, 2019 at 14:22 PM EDT
Ahead of a potential FDA approval of Duchenne muscular dystrophy drugmaker Sarepta’s second treatment, drug pricing watchdog group ICER may reopen old wounds by questioning whether the company's products help patients.
